437 related articles for article (PubMed ID: 15160337)
21. Toxicity, response rates and survival outcomes of induction cisplatin and irinotecan followed by concurrent cisplatin, irinotecan and radiotherapy for locally advanced esophageal cancer.
Watkins JM; Zauls AJ; Kearney PL; Shirai K; Ruppert BN; Harper JL; Sherman CA; Aguero EG; Reed CE; Sharma AK
Jpn J Clin Oncol; 2011 Mar; 41(3):334-42. PubMed ID: 21084436
[TBL] [Abstract][Full Text] [Related]
22. Safety, efficacy, and long-term follow-up evaluation of perioperative epirubicin, Cisplatin, and capecitabine chemotherapy in esophageal resection for adenocarcinoma.
van der Sluis PC; Ubink I; van der Horst S; Boonstra JJ; Voest EE; Ruurda JP; Borel Rinkes IH; Wiezer MJ; Schipper ME; Siersema PD; Los M; Lolkema MP; van Hillegersberg R
Ann Surg Oncol; 2015 May; 22(5):1555-63. PubMed ID: 25564156
[TBL] [Abstract][Full Text] [Related]
23. Preoperative Chemoradiotherapy Versus Perioperative Chemotherapy for Patients With Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma.
Anderegg MCJ; van der Sluis PC; Ruurda JP; Gisbertz SS; Hulshof MCCM; van Vulpen M; Mohammed NH; van Laarhoven HWM; Wiezer MJ; Los M; van Berge Henegouwen MI; van Hillegersberg R
Ann Surg Oncol; 2017 Aug; 24(8):2282-2290. PubMed ID: 28424936
[TBL] [Abstract][Full Text] [Related]
24. Prospective non-randomized study of preoperative concurrent platinum plus 5-fluorouracil-based chemoradiotherapy with or without paclitaxel in esophageal cancer patients: long-term follow-up.
Zemanova M; Petruzelka L; Pazdro A; Kralova D; Smejkal M; Pazdrova G; Honova H
Dis Esophagus; 2010 Feb; 23(2):160-7. PubMed ID: 19515190
[TBL] [Abstract][Full Text] [Related]
25. Phase II trial of preoperative irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for resectable locally advanced gastric and esophagogastric junction adenocarcinoma.
Rivera F; Galán M; Tabernero J; Cervantes A; Vega-Villegas ME; Gallego J; Laquente B; Rodríguez E; Carrato A; Escudero P; Massutí B; Alonso-Orduña V; Cardenal A; Sáenz A; Giralt J; Yuste AL; Antón A; Aranda E;
Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1430-6. PubMed ID: 19540072
[TBL] [Abstract][Full Text] [Related]
26. Long-term results of a phase II trial of neoadjuvant chemotherapy followed by esophagectomy for locally advanced esophageal neoplasm.
Pennathur A; Luketich JD; Landreneau RJ; Ward J; Christie NA; Gibson MK; Schuchert M; Cooper K; Land SR; Belani CP
Ann Thorac Surg; 2008 Jun; 85(6):1930-6; discussion 1936-7. PubMed ID: 18498797
[TBL] [Abstract][Full Text] [Related]
27. Long-term survival following induction chemoradiotherapy and esophagectomy for esophageal carcinoma.
Lew JI; Gooding WE; Ribeiro U; Safatle-Ribeiro AV; Posner MC
Arch Surg; 2001 Jul; 136(7):737-42; discussion 743. PubMed ID: 11448381
[TBL] [Abstract][Full Text] [Related]
28. Intensive preoperative chemotherapy with colony-stimulating factor for resectable adenocarcinoma of the esophagus or gastroesophageal junction.
Ajani JA; Roth JA; Ryan MB; Putnam JB; Pazdur R; Levin B; Gutterman JU; McMurtrey M
J Clin Oncol; 1993 Jan; 11(1):22-8. PubMed ID: 8418237
[TBL] [Abstract][Full Text] [Related]
29. Characterization of pathologic complete response after preoperative chemoradiotherapy in carcinoma of the esophagus and outcome after pathologic complete response.
Rohatgi P; Swisher SG; Correa AM; Wu TT; Liao Z; Komaki R; Walsh GL; Vaporciyan AA; Rice DC; Roth JA; Ajani JA
Cancer; 2005 Dec; 104(11):2365-72. PubMed ID: 16245310
[TBL] [Abstract][Full Text] [Related]
30. Enhanced staging and all chemotherapy preoperatively in patients with potentially resectable gastric carcinoma.
Ajani JA; Mansfield PF; Lynch PM; Pisters PW; Feig B; Dumas P; Evans DB; Raijman I; Hargraves K; Curley S; Ota DM
J Clin Oncol; 1999 Aug; 17(8):2403-11. PubMed ID: 10561303
[TBL] [Abstract][Full Text] [Related]
31. Survival and recurrence patterns after neoadjuvant docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophagogastric adenocarcinoma.
Sudarshan M; Alcindor T; Ades S; Aloraini A; van Huyse M; Asselah J; David M; Frechette D; Brisson S; Thirlwell M; Ferri L
Ann Surg Oncol; 2015 Jan; 22(1):324-30. PubMed ID: 25023544
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of pre- and postoperative chemotherapy for resectable adenocarcinoma of the esophagus or gastroesophageal junction.
Ajani JA; Roth JA; Ryan B; McMurtrey M; Rich TA; Jackson DE; Abbruzzese JL; Levin B; DeCaro L; Mountain C
J Clin Oncol; 1990 Jul; 8(7):1231-8. PubMed ID: 2358838
[TBL] [Abstract][Full Text] [Related]
33. A highly active and tolerable neoadjuvant regimen combining paclitaxel, carboplatin, 5-FU, and radiation therapy in patients with stage II and III esophageal cancer.
van de Schoot L; Romme EA; van der Sangen MJ; Creemers GJ; van Lijnschoten G; van Driel OJ; Rutten HJ; Nieuwenhuijzen GA
Ann Surg Oncol; 2008 Jan; 15(1):88-95. PubMed ID: 17896144
[TBL] [Abstract][Full Text] [Related]
34. Long-term outcome of phase II trial evaluating chemotherapy, chemoradiotherapy, and surgery for locoregionally advanced esophageal cancer.
Swisher SG; Ajani JA; Komaki R; Nesbitt JC; Correa AM; Cox JD; Lahoti S; Martin F; Putnam JB; Smythe WR; Vaporciyan AA; Walsh GL; Roth JA
Int J Radiat Oncol Biol Phys; 2003 Sep; 57(1):120-7. PubMed ID: 12909224
[TBL] [Abstract][Full Text] [Related]
35. Phase 2 trial of induction and concurrent chemoradiotherapy with weekly irinotecan and cisplatin followed by surgery for esophageal cancer.
Ilson DH; Minsky BD; Ku GY; Rusch V; Rizk N; Shah M; Kelsen DP; Capanu M; Tang L; Campbell J; Bains M
Cancer; 2012 Jun; 118(11):2820-7. PubMed ID: 21990000
[TBL] [Abstract][Full Text] [Related]
36. Comparison of locoregional versus extended locoregional radiation volumes for patients with nonmetastatic gastro-esophageal junction carcinomas.
Wang J; Milton DR; He L; Komaki R; Liao Z; Crane CH; Minsky BD; Thall PF; Lin SH
J Thorac Oncol; 2015 Mar; 10(3):518-26. PubMed ID: 25695222
[TBL] [Abstract][Full Text] [Related]
37. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer.
Swisher SG; Maish M; Erasmus JJ; Correa AM; Ajani JA; Bresalier R; Komaki R; Macapinlac H; Munden RF; Putnam JB; Rice D; Smythe WR; Vaporciyan AA; Walsh GL; Wu TT; Roth JA
Ann Thorac Surg; 2004 Oct; 78(4):1152-60; discussion 1152-60. PubMed ID: 15464463
[TBL] [Abstract][Full Text] [Related]
38. Phase II study of use of a single cycle of induction chemotherapy and concurrent chemoradiotherapy containing capecitabine/cisplatin followed by surgery for patients with resectable esophageal squamous cell carcinoma: long-term follow-up data.
Koo DH; Park SI; Kim YH; Kim JH; Jung HY; Lee GH; Choi KD; Song HJ; Song HY; Shin JH; Cho KJ; Yoon DH; Kim SB
Cancer Chemother Pharmacol; 2012 Mar; 69(3):655-63. PubMed ID: 21968953
[TBL] [Abstract][Full Text] [Related]
39. Final Results of NRG Oncology RTOG 0246: An Organ-Preserving Selective Resection Strategy in Esophageal Cancer Patients Treated with Definitive Chemoradiation.
Swisher SG; Moughan J; Komaki RU; Ajani JA; Wu TT; Hofstetter WL; Konski AA; Willett CG
J Thorac Oncol; 2017 Feb; 12(2):368-374. PubMed ID: 27729298
[TBL] [Abstract][Full Text] [Related]
40. Outcomes from chemoradiotherapy for patients with esophageal cancer.
Pantling AZ; Gossage JA; Mamidanna R; Newman G; Robinson A; Manifold DK; Hale PC
Dis Esophagus; 2011 Apr; 24(3):172-6. PubMed ID: 21073614
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
